Identification
- Summary
Mometasone furoate is a corticosteroid used to treat asthma, allergic rhinitis, nasal congestion, nasal polyps, dermatitis, and pruritus.
- Brand Names
- Asmanex, Dulera, Elocom, Elocon, Nasonex, Ryaltris, Sinuva, Zenhale
- Generic Name
- Mometasone furoate
- DrugBank Accession Number
- DB14512
- Background
Mometasone furoate is a corticosteroid drug that can be used for the treatment of asthma, rhinitis, and certain skin conditionsLabel14,15. It has a glucocorticoid receptor binding affinity 22 times stronger than dexamethasone and higher than many other corticosteroids as well2. Mometasone furoate is formulated as a dry powder inhaler, nasal spray, and ointment for its different indicationsLabel14,15.
- Type
- Small Molecule
- Groups
- Approved, Investigational, Vet approved
- Structure
Structure for Mometasone furoate (DB14512)
- Weight
- Average: 521.429
Monoisotopic: 520.141944106 - Chemical Formula
- C27H30Cl2O6
- Synonyms
- Mometasone furoate
- Mometasone furoate anhydrous
- External IDs
- SCH 32088
- SCH-32088
Pharmacology
- Indication
Inhaled mometasone furoate is indicated for prophylaxis of asthma in patients ≥4 years.5 Applied topically as an ointment, mometasone furoate is indicated for symptomatic treatment of dermatitis and pruritis in patients ≥2 years.9
Mometasone furoate nasal spray is available both over-the-counter (OTC) and by prescription. The OTC nasal spray formulation of mometasone furoate is indicated for the treatment of upper respiratory allergic symptoms (e.g. rhinorrhea, sneezing) in patients ≥2 years of age.11 The prescription formulation is indicated for the treatment of chronic rhinosinusitis with nasal polyps in patients ≥18 year old and for the and prophylaxis of seasonal allergic rhinitis in patients ≥12 years old.6 It is also approved in combination with olopatadine for the symptomatic treatment of seasonal allergic rhinitis in patients ≥12 years.10
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Management of Asthma •••••••••••• ••••••• ••••••• Prophylaxis of Chronic rhinosinusitis phenotype with nasal polyps (crswnp) •••••••••••• ••••• ••••• Used in combination to treat Dermatitis, eczematous caused by superficial fungal skin infection Combination Product in combination with: Terbinafine (DB00857) •••••••••••• ••••• Used in combination to treat Moderate to severe plaque psoriasis Combination Product in combination with: Salicylic acid (DB00936) •••••••••••• •••••••• Treatment of Pruritus •••••••••••• •••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Mometasone is a synthetic corticosteroid with an affinity for glucocorticoid receptors 22 times higher than that of dexamethasone2. Mometasone furoate also has a lower affinity to mineralocorticoid receptors than natural corticosteroids, making it more selective in its action2. Mometasone furoate diffuses across cell membranes to activate pathways responsible for reducing inflammationLabel1,2,3,14,15.
- Mechanism of action
In asthma, mometasone is believed to inhibit mast cells, eosinophils, basophils, and lymphocytes3. There is also evidence of inhibition of histamine, leukotrienes, and cytokines3.
Corticosteroids diffuse across cell membranes into the cytosol of cells where they bind to glucocorticoid receptors to produce their activity2. Mometasone furoate has a particularly high receptor affinity compare to other corticosteroids, 22 times higher than that of dexamethasone2. Mometasone furoate binding to a glucocorticoid receptor causes conformational changes in the receptor, separation from chaperones, and the receptor moves to the nucleus3. Once at the nucleus, receptors dimerize and bind to a DNA sequence known as the glucocorticoid response element which either increases expression of anti-inflammatory molecules or inhibits expression of pro-inflammatory molecules (such as interleukins 4 and 5)3. Mometasone furoate also reduces inflammation by blocking transcription factors such as activator-protein-1 and nuclear factor kappa B (NF-kappaB)2,3.
Target Actions Organism AGlucocorticoid receptor Not Available Humans UProgesterone receptor Not Available Humans - Absorption
The mean time to peak concentration is 1.0 to 2.5 hoursLabel. Bioavailability has been reported as <1%Label but studies of repeat doses of inhaled corticosteroids suggest a bioavailability of 11%3. The 0.1% ointment may have a bioavailability of 0.7%15.
- Volume of distribution
Steady state volume of distribution of 152LLabel.
- Protein binding
98% to 99% (in vitro concentration of 5 to 500ng/mL)Label14.
- Metabolism
Metabolism of mometasone furoate is largely performed hepatically by cytochrome P450 3A4 producing a number of metabolitesLabel14,1,3. Some of these metabolites include free mometasone and 6-beta-hydroxy-mometasone furoate1,3,4.
Hover over products below to view reaction partners
- Route of elimination
For an inhaled dose, approximately 74% is excreted in the feces and 8% is excreted in the urineLabel14.
- Half-life
The terminal half life of an inhaled dose is approximately 5 hoursLabel though it has been reported as 5.8 hours by other sources14,2.
- Clearance
The clearance rate of mometasone furoate is not readily available1, though it may be close to 90L/h2.
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Overdose with a mometasone furoate inhaler may occur with chronic overuseLabel14. Symptoms of chronic overuse may present as hypercorticism and adrenal suppression, and patients may not require any more treatment than monitoringLabel14.
In animal studies of pregnancy, some fetal toxic effects were seen at or above the maximum recommended human dose, though rodents are more sensitive to these effects than humansLabel14,15. The benefits and risks of use should be considered in pregnant patients14,15
It is unknown if mometasone furoate is excreted in breast milk but other corticosteroids are and therefore caution should be exercised when administering to nursing mothersLabel14,15.
Safety and effectiveness in pediatric populations has been established through clinical trials, though there may be a reduction in expected growth of about 1cm per year depending on the dose and duration of treatmentLabel. Pediatric patients should be titrated to the lowest effective dose for mometasone furoate inhalersLabel.
A trial of geriatric patients showed no difference in safety or efficacy compared to younger patients, however patients of an even greater age may still be more sensitive to mometasone furoateLabel14,15.
The use of a mometasone furoate inhaler in moderate or severe hepatic impairment rarely leads to detectable plasma concentrations though caution may be prudent with increasing degrees of severityLabel14.
The effects of mometasone furoate in renal impairment, and across gender and race have not been studiedLabel14.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbametapir The serum concentration of Mometasone furoate can be increased when it is combined with Abametapir. Abatacept The risk or severity of adverse effects can be increased when Abatacept is combined with Mometasone furoate. Abemaciclib The metabolism of Abemaciclib can be increased when combined with Mometasone furoate. Acalabrutinib The metabolism of Acalabrutinib can be increased when combined with Mometasone furoate. Acarbose The risk or severity of hyperglycemia can be increased when Mometasone furoate is combined with Acarbose. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Mometasone furoate monohydrate MTW0WEG809 141646-00-6 AQCCVUHZMIMSIB-HRVPQZBTSA-N - Active Moieties
Name Kind UNII CAS InChI Key Mometasone prodrug 8HR4QJ6DW8 105102-22-5 QLIIKPVHVRXHRI-CXSFZGCWSA-N - International/Other Brands
- Ecural (Essex pharma) / Elocom (Merck) / Elomet (Schering-Plough) / Eziwin (Intas) / mometAid (Progreś Laboratories) / Novasone (Schering-Plough)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Asmanex Inhalant 110 ug/1 Respiratory (inhalation) Merck Sharp & Dohme Corp. 2005-03-30 Not applicable US 
Asmanex Inhalant 220 ug/1 Respiratory (inhalation) Physicians Total Care, Inc. 2006-03-09 Not applicable US Asmanex Inhalant 220 ug/1 Respiratory (inhalation) Organon LLC 2021-06-01 Not applicable US Asmanex Inhalant 220 ug/1 Respiratory (inhalation) Merck Sharp & Dohme Corp. 2005-03-30 Not applicable US Asmanex Inhalant 110 ug/1 Respiratory (inhalation) Organon LLC 2021-06-01 Not applicable US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Apo-mometasone Spray, metered 50 mcg / act Nasal Apotex Corporation 2013-03-25 Not applicable Canada 
Mometasone Furoate Cream 1 mg/1g Topical Nucare Pharmaceuticals,inc. 2008-05-28 Not applicable US Mometasone Furoate Cream 1 mg/1g Topical A-S Medication Solutions 2006-08-23 Not applicable US Mometasone Furoate Ointment 1 mg/1g Topical Dispensing Solutions, Inc. 2006-10-18 Not applicable US Mometasone Furoate Ointment 1 mg/1g Topical bryant ranch prepack 2008-07-18 Not applicable US - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Allergy Nasal Spray 50 ug/1 Nasal Walgreen Company 2023-03-30 Not applicable US Childrens Nasonex Spray 50 ug/1 Nasal L. Perrigo Company 2023-02-07 Not applicable US Leader Nasal Spray 50 ug/1 Nasal Cardinal Health 110, LLC. DBA Leader 2023-09-22 Not applicable US Mometasone Furoate Spray, metered 50 ug/1 Nasal Amneal Pharmaceuticals NY LLC 2023-06-16 Not applicable US Mosaspray Spray, metered 50 mcg / act Nasal Sandoz Canada Incorporated 2016-06-17 2020-07-20 Canada - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Atectura Breezhaler Mometasone furoate (127.5 mcg) + Indacaterol acetate (125 mcg) Capsule Respiratory (inhalation) Novartis Europharm Limited 2023-02-08 Not applicable EU 
ATECTURA BREEZHALER Mometasone furoate (127.5 MCG) + Indacaterol acetate (125 MCG) Powder, metered Respiratory (inhalation) Novartis Europharm Limited 2020-09-10 Not applicable Italy 
Atectura Breezhaler Mometasone furoate (260 mcg) + Indacaterol acetate (125 mcg) Capsule Respiratory (inhalation) Novartis Europharm Limited 2020-12-16 Not applicable EU Atectura Breezhaler Mometasone furoate (127.5 mcg) + Indacaterol acetate (125 mcg) Capsule Respiratory (inhalation) Novartis Europharm Limited 2020-12-16 Not applicable EU ATECTURA BREEZHALER Mometasone furoate (260 MCG) + Indacaterol acetate (125 MCG) Powder, metered Respiratory (inhalation) Novartis Europharm Limited 2020-09-10 Not applicable Italy - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Hyaluronic Acid Sodium Salt 2% / Mometasone Furoate 0.1% / Niacinamide 4% Mometasone furoate (0.1 g/100g) + Hyaluronic acid (2 g/100g) + Nicotinamide (4 g/100g) Cream Topical Sincerus Florida, LLC 2019-05-21 Not applicable US Mometacure Mometasone furoate (1 mg/1g) + Dimethicone (5 g/100mL) Kit Topical Forreal Pharmaceuticals LLC 2023-09-13 Not applicable US
Categories
- ATC Codes
- D07AC13 — Mometasone
- D07AC — Corticosteroids, potent (group III)
- D07A — CORTICOSTEROIDS, PLAIN
- D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
- D — DERMATOLOGICALS
- R03BA — Glucocorticoids
- R03B — OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
- R03 — DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
- R — RESPIRATORY SYSTEM
- D07XC — Corticosteroids, potent, other combinations
- D07X — CORTICOSTEROIDS, OTHER COMBINATIONS
- D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
- D — DERMATOLOGICALS
- R01AD — Corticosteroids
- R01A — DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
- R01 — NASAL PREPARATIONS
- R — RESPIRATORY SYSTEM
- Drug Categories
- Adrenal Cortex Hormones
- Adrenals
- Adrenergics, Inhalants
- Anti-Allergic Agents
- Anti-Inflammatory Agents
- Corticosteroids
- Corticosteroids, Dermatological Preparations
- Corticosteroids, Potent (Group III)
- Cytochrome P-450 CYP2C8 Inhibitors
- Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)
- Cytochrome P-450 CYP2C8 Inhibitors (strong)
- Cytochrome P-450 CYP3A Inducers
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Inducers
- Cytochrome P-450 CYP3A4 Inducers (strength unknown)
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 CYP3A5 Inducers
- Cytochrome P-450 CYP3A5 Inducers (strength unknown)
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 Substrates
- Dermatologicals
- Drugs for Obstructive Airway Diseases
- Fused-Ring Compounds
- Glucocorticoids
- Hyperglycemia-Associated Agents
- Immunosuppressive Agents
- Nasal Preparations
- Pregnadienes
- Steroids
- Thyroxine-binding globulin inhibitors
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Pregnane steroids
- Direct Parent
- Gluco/mineralocorticoids, progestogins and derivatives
- Alternative Parents
- Steroid esters / 20-oxosteroids / 11-beta-hydroxysteroids / 3-oxo delta-1,4-steroids / Halogenated steroids / Delta-1,4-steroids / Furoic acid esters / Alpha-chloroketones / Heteroaromatic compounds / Secondary alcohols show 10 more
- Substituents
- 11-beta-hydroxysteroid / 11-hydroxysteroid / 20-oxosteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / 9-halo-steroid / Alcohol / Alkyl chloride / Alkyl halide / Alpha-chloroketone show 30 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- organochlorine compound, 11beta-hydroxy steroid, steroid ester, 20-oxo steroid, 3-oxo-Delta(1),Delta(4)-steroid, 2-furoate ester (CHEBI:47564)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 04201GDN4R
- CAS number
- 83919-23-7
- InChI Key
- WOFMFGQZHJDGCX-ZULDAHANSA-N
- InChI
- InChI=1S/C27H30Cl2O6/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20/h4-5,8-10,12,15,18-19,21,31H,6-7,11,13-14H2,1-3H3/t15-,18+,19+,21+,24+,25+,26+,27+/m1/s1
- IUPAC Name
- (1R,2R,3aS,3bS,9aS,9bR,10S,11aS)-9b-chloro-1-(2-chloroacetyl)-10-hydroxy-2,9a,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl furan-2-carboxylate
- SMILES
- [H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
References
- General References
- Szefler SJ: Pharmacokinetics of intranasal corticosteroids. J Allergy Clin Immunol. 2001 Jul;108(1 Suppl):S26-31. [Article]
- Hubner M, Hochhaus G, Derendorf H: Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin North Am. 2005 Aug;25(3):469-88. doi: 10.1016/j.iac.2005.05.004. [Article]
- Crim C, Pierre LN, Daley-Yates PT: A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clin Ther. 2001 Sep;23(9):1339-54. [Article]
- Teng XW, Cutler DJ, Davies NM: Mometasone furoate degradation and metabolism in human biological fluids and tissues. Biopharm Drug Dispos. 2003 Nov;24(8):321-33. doi: 10.1002/bdd.362. [Article]
- FDA Approved Drug Products: Asmanex Mometasone Furoate Inhalation Powder [Link]
- FDA Approved Drug Products: Nasonex (mometasone furoate) nasal spray [Link]
- FDA Approved Drug Products: Elocon Mometasone Furoate Lotion [Link]
- FDA Approved Drug Products: Sinuva Mometasone Furoate Sinus Implant [Link]
- FDA Approved Drug Products: Elocon Mometasone Furoate Ointment [Link]
- FDA Approved Drug Products: Ryaltris (olopatadine hydrochloride/mometasone furoate monohydrate) nasal spray [Link]
- FDA Approved Drug Products: Nasonex 24h Allergy (mometasone furoate) nasal spray (OTC) [Link]
- Health Canada Approved Drug Proucts: Ryaltris (olopatadine hydrochloride/mometasone furoate monohydrate) nasal spray [Link]
- FDA Approved Drug Products: SINUVA (mometasone furoate)sinus implant Jan 2023 [Link]
- Mometasone Furoate Nasonex FDA Label [File]
- Mometasone Furoate Elocon FDA Label [File]
- External Links
- KEGG Drug
- D00690
- KEGG Compound
- C07817
- ChemSpider
- 390091
- BindingDB
- 50148733
- ChEBI
- 47564
- ChEMBL
- CHEMBL1161
- ZINC
- ZINC000003938677
- PDBe Ligand
- MOF
- Wikipedia
- Mometasone
- PDB Entries
- 1sr7 / 4e2j / 4p6w
- FDA label
- Download (609 KB)
- MSDS
- Download (185 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Not Available Atopic Dermatitis 1 4 Completed Other Atopic Dermatitis 1 4 Completed Other Rhinitis, Allergic, Perennial and Seasonal 1 4 Completed Treatment Adenoidal Hypertrophy 1 4 Completed Treatment Adenoids 1
Pharmacoeconomics
- Manufacturers
- Schering corp sub schering plough corp
- Altana inc
- G and w laboratories inc
- Glenmark generics inc usa
- Taro pharmaceuticals usa inc
- Tolmar inc
- Nycomed us inc
- Perrigo co
- Perrigo new york inc
- Schering corp
- Schering plough healthcare products inc
- Schering-Plough
- Packagers
- A-S Medication Solutions LLC
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- Dixie Chem Tec Inc.
- E. Fougera and Co.
- G & W Labs
- Glenmark Generics Ltd.
- Harris Pharmaceutical Inc.
- JSJ Pharmaceuticals Inc.
- Lake Erie Medical and Surgical Supply
- Nycomed Inc.
- Perrigo Co.
- Pharmedix
- Physicians Total Care Inc.
- Sandoz
- Schering Corp.
- Schering-Plough Inc.
- Taro Pharmaceuticals USA
- Tolmar Inc.
- Dosage Forms
Form Route Strength Suspension Nasal 0.05000 g Suspension Nasal 0.050 g Spray, metered Nasal 50 mcg Inhalant Respiratory (inhalation) 110 ug/1 Inhalant Respiratory (inhalation) 220 ug/1 Aerosol Respiratory (inhalation) 100 ug/1 Aerosol Respiratory (inhalation) 200 ug/1 Aerosol Respiratory (inhalation) 50 ug/1 Aerosol, powder Respiratory (inhalation) 200 UG Aerosol, powder Respiratory (inhalation) 400 UG Powder Respiratory (inhalation) 100 mcg / act Powder Respiratory (inhalation) 200 mcg / act Powder Respiratory (inhalation) 400 mcg / act Powder, metered Respiratory (inhalation) 100 mcg/inhalation Powder, metered Respiratory (inhalation) 200 mcg/inhalation Powder Respiratory (inhalation) 200 Mikrogramm Powder Respiratory (inhalation) 200 mcg Powder, metered Respiratory (inhalation) 400 mcg/inhalation Powder Respiratory (inhalation) 400 Mikrogramm Capsule Respiratory (inhalation) Powder Buccal Lotion Topical Suspension Nasal 0.050 g Ointment Topical Suspension Nasal 0.50 mg Spray Nasal 0.05 % Emulsion Topical 0.1 g Lotion Topical 0.1 g Ointment Topical 0.1 mg Aerosol, metered Nasal 0.05 % Suspension Nasal 0.0005 g Suspension Nasal Aerosol Respiratory (inhalation) Solution Oral 1 mg/g Ointment Topical 1 mg/g Ointment Cutaneous 1.00 mg Lotion Topical 0.1 % Ointment Topical 1 mg Cream Topical 1 mg/1g Ointment Topical Ointment Topical 1 mg/1g Solution Topical Solution Topical 1 mg/g Cream 0.1 % Ointment 0.1 % Cream Topical 1 mg Ointment Cutaneous 1.000 mg/g Solution Cutaneous 0.100 g Ointment Topical 1 mg/g Cream Topical 0.10 % w/w Lotion Topical 0.10 % W/V Lotion Topical Ointment Topical 0.10 % w/w Powder Buccal 0.050 mg Powder, metered Respiratory (inhalation) Spray, suspension Nasal 0.05 % Spray, suspension Nasal 0.05 % w/v Gel Topical Cream Topical 10000000 mg Lotion Topical 100 mg Solution Topical 1 mg Suspension Nasal; Respiratory (inhalation) 50 cg Capsule, coated Oral Cream Topical Suspension Nasal 0.0500 g Suspension Nasal 0.05 g Powder Respiratory (inhalation) Capsule; powder Respiratory (inhalation) Ointment Cutaneous 0.001 g Cream Topical 1.0 mg/g Gel Cream Cutaneous 100.000 mg Powder Respiratory (inhalation) 400 mcg Spray Nasal Cream Topical 0.1 % Ointment Topical 0.1 %w/w Spray Nasal 50 UG Suspension Intrasinal; Nasal 50 mcg Spray Nasal 50 mcg/actuation Ointment Topical 0.1 % Lotion Topical 0.094 g Lotion Topical 0.101 g Spray, suspension Nasal 50 mcg/puff Spray Nasal 50 Mikrogramm Spray, suspension Nasal 50 mcg/0.1ml Cream Topical 0.1 g Cream Topical 100 mg Lotion Topical 100 g Cream Topical 1 g/100g Lotion Topical 1 mg/1mL Lotion Topical 1 mg/1g Ointment Topical 1 mg/1 Solution Topical 1 mg/1mL Spray, suspension Nasal 50 mcg/1dose Spray, suspension Nasal 50 mcg/actuation Spray, suspension Nasal 50 mcg Suspension Respiratory (inhalation) 0.05 g Suspension Intrasinal; Nasal 0.05 g Solution; spray Nasal 0.05 % Spray, suspension Nasal 50 mcg/spray Ointment Topical 0.1 g Cream Topical Emulsion Topical Aerosol, metered Respiratory (inhalation) Cream Cutaneous 1 MG/G Spray, metered Nasal 50 mcg / spray Spray Nasal 50 ug/1 Spray, metered Nasal 50 ug/1 Spray Nasal 0.05 mg Spray, metered Nasal 50 mcg / act Spray Nasal 50 mcg Spray Nasal 140 doz Spray, suspension Nasal 50 μg Cream Topical .1 % Lotion Topical .1 % Powder Respiratory (inhalation) 200 cg Powder Respiratory (inhalation) 400 cg Cream; kit Topical Kit Topical Suspension Intrasinal; Respiratory (inhalation) 50 mg Solution Intrasinal; Respiratory (inhalation) 0.05 g Suspension Intrasinal; Respiratory (inhalation) 0.05 g Suspension Nasal; Topical 0.05 % Spray, metered Nasal Implant Intrasinal 1350 ug/1 Ointment Cutaneous 100.000 mg Cream Topical 0.1 % w/w Lotion Topical 0.1 % w/w Cream Topical 1 mg/g Ointment Topical 0.1 % W/W Ointment Cutaneous 0.100 g Suspension Nasal 0.500 mg Cream 0.1 %w/w - Prices
Unit description Cost Unit Asmanex 120 Metered Doses 220 mcg/inh Aerosol 0.24 gm Inhaler 230.27USD inhaler Asmanex twisthaler 220 mcg #30 131.47USD inhaler Asmanex twisthaler 110 mcg #30 121.76USD inhaler Nasonex 50 mcg/act Suspension 50 mcg Nasal Spray 116.82USD inhaler Elocon 0.1% Lotion 60ml Bottle 86.71USD bottle Elocon 0.1% Cream 45 gm Tube 79.13USD tube Elocon 0.1% Ointment 45 gm Tube 76.45USD tube Mometasone Furoate 0.1% Solution 60ml Bottle 64.99USD bottle Mometasone Furoate 0.1% Cream 45 gm Tube 50.96USD tube Elocon 0.1% Lotion 30ml Bottle 49.85USD bottle Elocon 0.1% Ointment 15 gm Tube 49.85USD tube Elocon 0.1% Cream 15 gm Tube 47.68USD tube Mometasone Furoate 0.1% Ointment 45 gm Tube 35.99USD tube Mometasone Furoate 0.1% Solution 30ml Bottle 32.99USD bottle Mometasone Furoate 0.1% Cream 15 gm Tube 29.99USD tube Mometasone Furoate 0.1% Ointment 15 gm Tube 19.19USD tube Nasonex 50 mcg nasal spray 6.37USD g Elocon 0.1% cream 2.69USD g Mometasone furoate 0.1% cream 1.42USD g Elocom 0.1 % Cream 0.7USD g Elocom 0.1 % Ointment 0.63USD g Elocom 0.1 % Lotion 0.47USD g Pms-Mometasone 0.1 % Ointment 0.35USD g Ratio-Mometasone 0.1 % Ointment 0.35USD g Taro-Mometasone 0.1 % Ointment 0.35USD g Taro-Mometasone 0.1 % Lotion 0.33USD g DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US6127353 Yes 2000-10-03 2018-04-03 US US6240918 Yes 2001-06-05 2017-08-20 US US8173172 Yes 2012-05-08 2018-09-17 US US6503537 Yes 2003-01-07 2018-09-17 US US5829434 Yes 1998-11-03 2016-05-03 US US6068832 No 2000-05-30 2017-08-27 US US7067502 Yes 2006-06-27 2020-11-21 US US7566705 Yes 2009-07-28 2020-11-21 US US8109918 No 2012-02-07 2024-03-12 US US7951131 No 2011-05-31 2024-03-12 US US8025635 No 2011-09-27 2027-06-12 US US9585681 No 2017-03-07 2026-04-04 US US7951130 No 2011-05-31 2024-03-12 US US7544192 No 2009-06-09 2026-11-29 US US7951133 No 2011-05-31 2024-03-12 US US7713255 No 2010-05-11 2024-03-12 US US7662141 No 2010-02-16 2024-03-12 US US8763222 No 2014-07-01 2032-02-08 US US10232152 No 2019-03-19 2034-11-24 US US10406332 No 2019-09-10 2034-03-13 US US10357640 No 2019-07-23 2031-10-03 US US10765686 No 2020-09-08 2034-09-04 US US10758550 No 2020-09-01 2034-09-04 US US10646500 No 2020-05-12 2034-09-04 US US10548907 No 2020-02-04 2034-09-04 US US10016443 No 2018-07-10 2034-09-04 US US10517880 No 2019-12-31 2034-09-04 US US9750754 No 2017-09-05 2034-09-04 US US9078923 No 2015-07-14 2034-09-04 US US9937189 No 2018-04-10 2034-09-04 US US10376526 No 2019-08-13 2034-09-04 US US9370483 No 2016-06-21 2034-09-04 US US10561672 No 2020-02-18 2034-09-04 US US11400101 No 2014-09-04 2034-09-04 US US11679210 No 2018-09-03 2038-09-03 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 215-228 Not Available water solubility Insoluble Not Available logP 4.115 Not Available - Predicted Properties
Property Value Source Water Solubility 0.0108 mg/mL ALOGPS logP 4.27 ALOGPS logP 5.06 Chemaxon logS -4.7 ALOGPS pKa (Strongest Acidic) 13.84 Chemaxon pKa (Strongest Basic) -3.1 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 93.81 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 132.5 m3·mol-1 Chemaxon Polarizability 52.31 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 212.77985 predictedDeepCCS 1.0 (2019) [M+H]+ 214.63326 predictedDeepCCS 1.0 (2019) [M+Na]+ 220.83252 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- General Function
- Zinc ion binding
- Specific Function
- Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
- Gene Name
- NR3C1
- Uniprot ID
- P04150
- Uniprot Name
- Glucocorticoid receptor
- Molecular Weight
- 85658.57 Da
References
- Isogai M, Shimizu H, Esumi Y, Terasawa T, Okada T, Sugeno K: Binding affinities of mometasone furoate and related compounds including its metabolites for the glucocorticoid receptor of rat skin tissue. J Steroid Biochem Mol Biol. 1993 Feb;44(2):141-5. [Article]
- Lumry WR: A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis. J Allergy Clin Immunol. 1999 Oct;104(4 Pt 1):S150-8. [Article]
- Smith CL, Kreutner W: In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittelforschung. 1998 Sep;48(9):956-60. [Article]
- Zhang X, Moilanen E, Adcock IM, Lindsay MA, Kankaanranta H: Divergent effect of mometasone on human eosinophil and neutrophil apoptosis. Life Sci. 2002 Aug 16;71(13):1523-34. [Article]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
- Mometasone Furoate Twisthaler Label [File]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Zinc ion binding
- Specific Function
- The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor ...
- Gene Name
- PGR
- Uniprot ID
- P06401
- Uniprot Name
- Progesterone receptor
- Molecular Weight
- 98979.96 Da
References
- Madauss KP, Deng SJ, Austin RJ, Lambert MH, McLay I, Pritchard J, Short SA, Stewart EL, Uings IJ, Williams SP: Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes. J Med Chem. 2004 Jun 17;47(13):3381-7. [Article]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C8
- Uniprot ID
- P10632
- Uniprot Name
- Cytochrome P450 2C8
- Molecular Weight
- 55824.275 Da
References
- Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [Article]
- Backman JT, Filppula AM, Niemi M, Neuvonen PJ: Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. Pharmacol Rev. 2016 Jan;68(1):168-241. doi: 10.1124/pr.115.011411. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- SubstrateInducer
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Berger WE, Milgrom H, Chervinsky P, Noonan M, Weinstein SF, Lutsky BN, Staudinger H: Effects of treatment with mometasone furoate dry powder inhaler in children with persistent asthma. Ann Allergy Asthma Immunol. 2006 Nov;97(5):672-80. doi: 10.1016/S1081-1206(10)61099-X. [Article]
- Sharpe M, Jarvis B: Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma. Drugs. 2001;61(9):1325-50. [Article]
- Dvorak Z, Pavek P: Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. doi: 10.3109/03602532.2010.484462. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Inducer
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A5
- Uniprot ID
- P20815
- Uniprot Name
- Cytochrome P450 3A5
- Molecular Weight
- 57108.065 Da
References
- Dvorak Z, Pavek P: Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. doi: 10.3109/03602532.2010.484462. [Article]
Drug created at July 12, 2018 15:10 / Updated at February 20, 2024 23:55